Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials

Autor:	Gary T. Ferguson, Nicola Brown, Chris Compton, Thomas C. Corbridge, Kelly Dorais, Charles Fogarty, Catherine Harvey, Morrys C. Kaisermann, David A. Lipson, Neil Martin, Frank Sciurba, Marjorie Stiegler, Chang-Qing Zhu, David Bernstein
Jazyk:	angličtina
Rok vydání:	2020
Předmět:	Triple therapy COPD Lung function Symptoms Long-acting β2-agonist (LABA) Long-acting muscarinic antagonist (LAMA) Diseases of the respiratory system RC705-779
Zdroj:	Respiratory Research, Vol 21, Iss 1, Pp 1-15 (2020)
Druh dokumentu:	article
ISSN:	1465-993X
DOI:	10.1186/s12931-020-01360-w
Popis:	Abstract Background The comparative efficacy of inhaled corticosteroid/long-acting muscarinic antagonist/long-acting β2-agonist (ICS/LAMA/LABA) triple therapy administered via single or multiple inhalers in patients with chronic obstructive pulmonary disease (COPD) has not been evaluated comprehensively. We conducted two replicate trials comparing single- with multiple-inhaler ICS/LAMA/LABA combination in COPD. Methods 207608 and 207609 were Phase IV, 12-week, randomized, double-blind, triple-dummy non-inferiority trials comparing once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 μg via Ellipta inhaler, with twice-daily budesonide/formoterol (BUD/FOR) 400/12 μg via metered-dose inhaler plus once-daily tiotropium (TIO) 18 μg via HandiHaler. Patients had symptomatic COPD and forced expiratory volume in 1 s (FEV1)
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/41a8de2104034afa8ba6a8ae1c6a62f7 Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.